COVID-19 severityin patients with diabetes and cardiovascular diseases: A Short Review

Authors

  • Houda EL ALAMI Environmental Health Laboratory, Institut Pasteur du Moroc, Casablanca, Morocco. Laboratory of Chemistry, Biochemistry, Nutrition, and Environment, Faculty of Medicine and Pharmacy, University Hassan II, Casablanca, Morocco cImmunovirology laboratory, Institut Pasteur du Moroc, Casablanca, Morocco
  • Lahcen WAKRIM Immunovirology laboratory, Institut Pasteur du Moroc, Casablanca, Morocco.
  • Hassan GHAZAL CNRST, Rabat, Morocco
  • Omar ABIDI Institut Pasteur du Moroc, Casablanca, Morocc
  • Naima KHLIL nstitut Pasteur du Moroc, Casablanca, Morocco
  • Abderrahman NAAMANE Laboratory of Chemistry, Biochemistry, Nutrition, and Environment, Faculty of Medicine and Pharmacy, University Hassan II, Casablanca, Morocco
  • Abderahmane MAAROUFI Institut Pasteur du Moroc, Casablanca, Morocco
  • Salsabil HAMDI Institut Pasteur du Moroc, Casablanca, Morocco

DOI:

https://doi.org/10.34874/PRSM.mjph-vol1iss1.24188

Keywords:

COVID-19, Diabetes mellitus, Cardiovascular diseases, ACE2

Abstract

A novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) has been become a global health hazard and declared as a pandemic disease by WHO. Patients with Covid-19 and pre-existing medical conditions like cardiovascular diseases, diabetes mellitus and hypertension have an increased risk of severe disease and death. Furthermore, the increased expression of Angiotensin -converting enzyme 2 (ACE-2) in patients with diabetes or cardiovascular diseases could increase the risk of severe infection with SARS-CoV-2.

Downloads

Published

25-12-2020

Issue

Vol. 1 No. 1 (2020): Special issue on emerging COVID-19

Section

Articles